These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26082022)

  • 21. Active hexose correlated compound modulates LPS-induced hypotension and gut injury in rats.
    Doursout MF; Liang Y; Sundaresan A; Wakame K; Fujii H; Takanari J; Devakottai S; Kulkarni A
    Int Immunopharmacol; 2016 Oct; 39():280-286. PubMed ID: 27500458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active hexose correlated compound exerts therapeutic effects in lymphocyte driven colitis.
    Mascaraque C; Suárez MD; Zarzuelo A; Sánchez de Medina F; Martínez-Augustin O
    Mol Nutr Food Res; 2014 Dec; 58(12):2379-82. PubMed ID: 25186628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
    Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
    Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
    Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
    J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of prophylactic CpG Oligodeoxynucleotide application on implant-associated Staphylococcus aureus bone infection.
    Sethi S; Thormann U; Sommer U; Stötzel S; Mohamed W; Schnettler R; Domann E; Chakraborty T; Alt V
    Bone; 2015 Sep; 78():194-202. PubMed ID: 25959416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma.
    Matsushita K; Kuramitsu Y; Ohiro Y; Obara M; Kobayashi M; Li YQ; Hosokawa M
    Anticancer Drugs; 1998 Apr; 9(4):343-50. PubMed ID: 9635925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration.
    Kim DH; Moon C; Oh SS; Park S; Jeong JW; Kim S; Lee HG; Kwon HJ; Kim KD
    Nucleic Acid Ther; 2015 Apr; 25(2):95-102. PubMed ID: 25692533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
    Kajiwara A; Doi H; Eguchi J; Ishii S; Hiraide-Sasagawa A; Sakaki M; Omori R; Hiroishi K; Imawari M
    Oncol Rep; 2012 Jun; 27(6):1765-71. PubMed ID: 22426807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
    Buhtoiarov IN; Sondel PM; Wigginton JM; Buhtoiarova TN; Yanke EM; Mahvi DA; Rakhmilevich AL
    Immunology; 2011 Feb; 132(2):226-39. PubMed ID: 21039467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active Hexose Correlated Compound Activates Immune Function to Decrease
    Belay T; Fu CL; Woart A
    J Nutr Med Diet Care; 2015; 1(1):. PubMed ID: 27790645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment.
    Cowawintaweewat S; Manoromana S; Sriplung H; Khuhaprema T; Tongtawe P; Tapchaisri P; Chaicumpa W
    Asian Pac J Allergy Immunol; 2006 Mar; 24(1):33-45. PubMed ID: 16913187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
    Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
    Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active hexose correlated compound activates immune function to decrease bacterial load in a murine model of intramuscular infection.
    Aviles H; O'Donnell P; Orshal J; Fujii H; Sun B; Sonnenfeld G
    Am J Surg; 2008 Apr; 195(4):537-45. PubMed ID: 18304499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    Najar HM; Dutz JP
    J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth.
    Chaudhry UI; Kingham TP; Plitas G; Katz SC; Raab JR; DeMatteo RP
    Cancer Res; 2006 Nov; 66(21):10497-504. PubMed ID: 17079471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.